Priceline.com Inc. (PCLN) Falls 2.81% for January 07

Equities Staff |

One of the S&P 500’s big losers for Thursday January 07 was Priceline.com Inc. (PCLN). The company’s stock fell 2.81% to $1,163.06 on volume of 851,340 shares.

The stock opened the day at 1,171.97 and traded between a low of $1,154.28 and a high of $1,194.49. The stock finished the day down $33.65 per share. Priceline.com Inc. has an average daily volume of 617,336 and a total float of 49.78 million shares. The 50-day SMA for Priceline.com Inc. is $1,313.82 and its 200-day SMA is $1,248.62. The high for the stock over the last 52 weeks is $1,476.52 and the low is $990.69.

Priceline Group Inc is a provider of online travel and travel related reservation and search services. The Company offer consumers accommodation reservations through its Booking.com, priceline.com and agoda.com brands.

Priceline.com Inc. is centered in Norwalk, CT, and has 15,500 employees. Today’s trading day leaves the company with a market cap of $57.9 billion. The company has a P/S ratio of n/a, P/B ratio of 6.71, and a 30.4.

For a complete fundamental analysis analysis of Priceline.com Inc., check out Equities.com’s Stock Valuation Analysis report for PCLN. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Veritas Pharma Inc.

Veritas Pharma Inc, formerly Seashore Organic Medicine Inc is an emerging producer and distributor of medical marijuana.

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…